Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Trial of MK-1248 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors.

NCT02553499 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT02553499
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02553499 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Trial of MK-1248 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors.
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 1
Overall status
Terminated
Start date
November 12, 2015
Completion date
October 17, 2018
Enrollment
37 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor